ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39668367

Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.

Mehta K and 8 others. Mil Med Res, 2024. Cited by 15 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials. Papers, record 39668367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39668367

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.
PubMed
Journal
Mil Med Res
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
2.39, provisional
iCite
Revised in PubMed
2026-05-28
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mehta KKasshish
2Hegde MMangala
3Girisa SSosmitha
4Vishwa RRavichandran
5Alqahtani MSMohammed S
6Abbas MMohamed
7Shakibaei MMehdi
8Sethi GGautamhttps://orcid.org/0000-0002-8677-8475
9Kunnumakkara ABAjaikumar Bhttps://orcid.org/0000-0001-9121-6816

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptor Protein-Tyrosine KinasesMajor topic
Triple Negative Breast NeoplasmsMajor topic
Female
Humans
Clinical Trials as Topic
Protein-Tyrosine Kinases

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References179

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,182,538
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol2023https://conductscience.org/library/papers/37182538PubMed
231,570,268Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.Clin Breast Cancer2020https://conductscience.org/library/papers/31570268PubMed
327,569,274Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.Clin Breast Cancer2016https://conductscience.org/library/papers/27569274PubMed
415,920,544EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.Mod Pathol2005https://conductscience.org/library/papers/15920544PubMed
525,349,977Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Br J Cancer2015https://conductscience.org/library/papers/25349977PubMed
624,091,128A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.Breast2013https://conductscience.org/library/papers/24091128PubMed
720,164,688Triple-negative breast cancer: role of antiangiogenic agents.Cancer J2010https://conductscience.org/library/papers/20164688PubMed
829,879,283Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.JAMA Oncol2018https://conductscience.org/library/papers/29879283PubMed
925,680,198Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.PLoS One2015https://conductscience.org/library/papers/25680198PubMed
1023,960,813The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab).Saudi Pharm J2012https://conductscience.org/library/papers/23960813PubMed

1 to 10 of 179

See all 179 references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42,964,571Breast cancer adaptation to oxygen stress: mechanisms of tumor survival, progression, and therapeutic resistance.Oncol Rev2026https://conductscience.org/library/papers/42964571PubMed
42,376,245Self-assembled manganese-based nanoplatforms synergizing immunogenic cell death and STING activation for triple-negative breast cancer.Mater Today Bio2026https://conductscience.org/library/papers/42376245PubMed
42,303,626Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42303626PubMed
41,814,321Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/41814321PubMed
41,757,567Tumor microenvironment and key signaling pathways in breast cancer progression and therapy resistance: A review.Biomol Biomed2026https://conductscience.org/library/papers/41757567PubMed
41,559,711Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/41559711PubMed
41,482,385N-myristoyltransferase 1-mediated Src Myristoylation Promotes Non-receptor Tyrosine Kinase Pathways in Oral Squamous Cell Carcinoma.In Vivo2026https://conductscience.org/library/papers/41482385PubMed
41,137,391DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC.Mol Ther2026https://conductscience.org/library/papers/41137391PubMed
41,088,941Breaking Barriers in Breast Cancer: Multi-Targeted Therapeutic Insights.Mini Rev Med Chem2025https://conductscience.org/library/papers/41088941PubMed
40,869,392Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALS.Int J Mol Sci2025https://conductscience.org/library/papers/40869392PubMed

1 to 10 of 12

See all 12 cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
KDR3,791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
MET4,233PubTator's text mininghttps://conductscience.org/library/genes/4233NCBI Gene
VEGFA7,422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39668367

GET https://conductscience.org/api/papers/v1/39668367/references?page=2

API referenceFor AI assistants